Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease.

Di Pardo A, Castaldo S, Amico E, Pepe G, Marracino F, Capocci L, Giovannelli A, Madonna M, van Bergeijk J, Buttari F, van der Kam E, Maglione V.

Hum Mol Genet. 2018 Jul 15;27(14):2490-2501. doi: 10.1093/hmg/ddy153.

PMID:
29688337
2.

Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.

Fatoba O, Kloster E, Reick C, Saft C, Gold R, Epplen JT, Arning L, Ellrichmann G.

Exp Neurol. 2018 Apr;302:112-128. doi: 10.1016/j.expneurol.2018.01.001. Epub 2018 Jan 6.

PMID:
29309751
3.

Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.

Ginés S, Bosch M, Marco S, Gavaldà N, Díaz-Hernández M, Lucas JJ, Canals JM, Alberch J.

Eur J Neurosci. 2006 Feb;23(3):649-58.

PMID:
16487146
4.

Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.

Reick C, Ellrichmann G, Tsai T, Lee DH, Wiese S, Gold R, Saft C, Linker RA.

Exp Neurol. 2016 Nov;285(Pt A):12-23. doi: 10.1016/j.expneurol.2016.08.012. Epub 2016 Aug 29.

PMID:
27587303
5.

Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

Jin J, Albertz J, Guo Z, Peng Q, Rudow G, Troncoso JC, Ross CA, Duan W.

J Neurochem. 2013 May;125(3):410-9. doi: 10.1111/jnc.12190. Epub 2013 Mar 5.

6.

The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.

Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, Duan W.

Exp Neurol. 2008 Mar;210(1):154-63. Epub 2007 Nov 9.

7.

Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease.

Shekhar S, Vatsa N, Kumar V, Singh BK, Jamal I, Sharma A, Jana NR.

Hum Mol Genet. 2017 Jan 15;26(2):420-429. doi: 10.1093/hmg/ddw398.

PMID:
28007908
8.

Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.

Gharami K, Xie Y, An JJ, Tonegawa S, Xu B.

J Neurochem. 2008 Apr;105(2):369-79. Epub 2007 Dec 12.

9.

2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease.

Wu B, Jiang M, Peng Q, Li G, Hou Z, Milne GL, Mori S, Alonso R, Geisler JG, Duan W.

Exp Neurol. 2017 Jul;293:83-90. doi: 10.1016/j.expneurol.2017.03.020. Epub 2017 Mar 28.

PMID:
28359739
11.

Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice.

Zajac MS, Pang TY, Wong N, Weinrich B, Leang LS, Craig JM, Saffery R, Hannan AJ.

Hippocampus. 2010 May;20(5):621-36. doi: 10.1002/hipo.20658.

PMID:
19499586
12.

A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.

Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S.

Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16685-9. Epub 2007 Oct 9.

13.

The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.

Doria JG, de Souza JM, Andrade JN, Rodrigues HA, Guimaraes IM, Carvalho TG, Guatimosim C, Dobransky T, Ribeiro FM.

Neurobiol Dis. 2015 Jan;73:163-73. doi: 10.1016/j.nbd.2014.08.021. Epub 2014 Aug 24.

PMID:
25160573
14.

Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.

Wang SE, Lin CL, Hsu CH, Sheu SJ, Chien CT, Wu CH.

Drug Des Devel Ther. 2015 Feb 16;9:887-900. doi: 10.2147/DDDT.S78015. eCollection 2015.

15.

Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.

Ferrante A, Martire A, Pepponi R, Varani K, Vincenzi F, Ferraro L, Beggiato S, Tebano MT, Popoli P.

Neurobiol Dis. 2014 Nov;71:193-204. doi: 10.1016/j.nbd.2014.08.013. Epub 2014 Aug 15.

PMID:
25132555
16.

Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.

Jin J, Peng Q, Hou Z, Jiang M, Wang X, Langseth AJ, Tao M, Barker PB, Mori S, Bergles DE, Ross CA, Detloff PJ, Zhang J, Duan W.

Hum Mol Genet. 2015 May 1;24(9):2508-27. doi: 10.1093/hmg/ddv016. Epub 2015 Jan 21.

17.

Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.

Jiang M, Peng Q, Liu X, Jin J, Hou Z, Zhang J, Mori S, Ross CA, Ye K, Duan W.

Hum Mol Genet. 2013 Jun 15;22(12):2462-70. doi: 10.1093/hmg/ddt098. Epub 2013 Feb 27.

18.

A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Simmons DA, Belichenko NP, Yang T, Condon C, Monbureau M, Shamloo M, Jing D, Massa SM, Longo FM.

J Neurosci. 2013 Nov 27;33(48):18712-27. doi: 10.1523/JNEUROSCI.1310-13.2013. Erratum in: J Neurosci. 2014 Jan 29;34(5):2012.

19.

Improvement of BDNF signalling by P42 peptide in Huntington's disease.

Couly S, Paucard A, Bonneaud N, Maurice T, Benigno L, Jourdan C, Cohen-Solal C, Vignes M, Maschat F.

Hum Mol Genet. 2018 Sep 1;27(17):3012-3028. doi: 10.1093/hmg/ddy207.

PMID:
29860423
20.

Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.

Brito V, Puigdellívol M, Giralt A, del Toro D, Alberch J, Ginés S.

Cell Death Dis. 2013 Apr 18;4:e595. doi: 10.1038/cddis.2013.116.

Supplemental Content

Support Center